The evolving role of PET/CT for prognostication in patients with lung cancer
1325 Learning Objectives 1. To review and summarize the benefit of PET/CT for prediction of the prognosis and outcome in lung cancer patients 2. To discuss the value of volumetric PET parameters such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG) for prognostication of lung cancer patients. 3. To review the prognostic value of multiple time point and delayed time points PET/CT imaging in patients with lung cancer. 4. To review the potential role of non-FDG PET tracers such as hypoxic and proliferation markers for prognostication of lung cancer. Lung cancer is the most common cause of cancer-related deaths in the United States and worldwide. PET/CT has an important role for diagnosis, restaging, treatment planning and evaluating treatment response. PET findings before and after treatment, quantitative PET parameters such as SUV, MTV and TLG, and the delayed time points imaging technique of PET/CT were studied for prognostic and outcome prediction. Moreover, non-FDG PET tracers can be used to determine prognostication. This review article provides the summary of PET/CT for prediction of prognosis and outcome in non-small cell lung cancer and small cell lung cancer patients. In this exhibit, we will discuss following topics: 1. PET’s role in treatment monitoring 2. PET’s role in prediction of the treatment outcome and treatment response 3. PET’s role as prognostic predictor at diagnosis, after induction therapy and for recurrent disease : a. PET parameters: SUVmax, SUVmean, MTV, TLG b. Delayed PET/CT imaging technique 4. Non-FDG PET tracers for prognostication